How Much Does Ibrance Cost With Medicare?
Ibrance (Palbociclib) costs an average of $10,816 per Medicare Part D claim, with total Medicare spending of $4521.0M in the latest year. A generic version is available, which may reduce out-of-pocket costs.
Key Facts: Ibrance Cost
- Medicare Part D avg
- $10,816/claim
- Likely Part D tier
- Tier 4-5 (specialty)
- Annual cost/patient
- $125,583
- Generic available
- Yes — Palbociclib
- Manufacturer
- Pfizer
- Treats
- Cancer
- YoY price change
- -5.6%
Source: CMS Medicare Part D Spending Dashboard. Tier placement inferred from typical formulary norms — confirm with your specific Part D plan.
Ibrance Medicare Coverage & Out-of-Pocket Cost
Ibrance is covered under Medicare Part D, with the program paying an average of $10,816 per prescription fill. Ibrance typically falls on Tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000.
Your actual out-of-pocket cost depends on three factors: (1) formulary tier — your plan's specific placement; (2) deductible status — most plans require you to meet up to a $590 deductible (2025) before copays kick in; (3) coverage phase — initial coverage, then the donut hole was eliminated in 2025, replaced by a hard $2,000 annual out-of-pocket cap under the Inflation Reduction Act. Once you hit $2,000 in true out-of-pocket spending, the rest of your Part D drugs are free for the year.
Because generic Palbociclib is available, the single biggest savings move is asking your pharmacist about generic substitution. Generics typically sit on Tier 1 with copays under $10, vs Tier 2-3 placement for brand-name Ibrance. Most states allow automatic substitution unless your prescriber writes "dispense as written."
For cash-pay or commercial insurance scenarios, compare prices using GoodRx, SingleCare, or Cost Plus Drugs before filling — discount-program prices sometimes beat Part D copays for lower-cost generics.
Ibrance is manufactured by Pfizer and prescribed primarily for Cancer. In the most recent Medicare Part D data, 418,000 claims were filed for 36,000 unique beneficiaries, at an average cost of $10,816 per claim. Average annual cost per beneficiary is $125,583.
Year over year, Medicare spending on Ibrance has decreased by -5.6%. Because a generic version of Palbociclib is available, patients can often substitute to reduce out-of-pocket costs. Its patent expires 2023-01-31.
Ibrance belongs to the Cancer Immunotherapy & Targeted Therapy class. Checkpoint inhibitors (Keytruda, Opdivo) unleash the immune system to attack cancer by blocking proteins (PD-1/PD-L1) that cancer cells use to hide. Kinase inhibitors (Ibrance, Xtandi) block specific enzymes that drive cancer cell growth. IMiDs (Revlimid) modify the immune system and directly kill cancer cells. CDK4/6 inhibitors (Ibrance, Kisqali) stop cancer cells from dividing.
Key Data
| Metric | Value |
|---|---|
| Avg Cost Per Claim | $10,816 |
| Total Medicare Spending | $4521.0M |
| Total Claims | 418,000 |
| Beneficiaries | 36,000 |
| Generic Available | Yes |
| Year-Over-Year Change | -5.6% |
Other Drugs for Cancer
Frequently Asked Questions
Medicare Part D pays an average of $10,816 per claim for Ibrance. Ibrance is typically placed on Tier 4-5 (specialty) of standard Part D formularies. Specialty drugs use coinsurance (25-33% of plan-negotiated price), not flat copays. The 2025 Part D annual out-of-pocket cap is $2,000. As of 2025, total annual out-of-pocket on Part D is capped at $2,000 under the Inflation Reduction Act.
Yes. Ibrance appears in Medicare Part D claims data, with 36,000 beneficiaries filling 418,000 prescriptions in the latest year. Specific coverage depends on your plan's formulary — call the number on your insurance card or check the plan's Summary of Benefits to confirm prior authorization, step therapy, or quantity limit requirements.
Ibrance (Palbociclib) costs an average of $10,816 per Medicare Part D claim, with total Medicare spending of $4521.0M in the latest year. A generic version is available, which may reduce out-of-pocket costs.
Yes. A generic version of Palbociclib is available, which typically costs 80-95% less than brand-name Ibrance. Ask your pharmacist about generic substitution — most state laws allow automatic substitution unless your prescriber writes "dispense as written."
Medicare beneficiaries cannot use manufacturer copay cards (anti-kickback statute), but several options exist: (1) Apply to charity copay foundations like the PAN Foundation, NeedyMeds, HealthWell Foundation, or Patient Advocate Foundation — many cover cancer drugs; (2) Ask your prescriber about therapeutic alternatives in the same drug class that may be on a lower tier; (3) For some drugs, paying cash via GoodRx or Cost Plus Drugs can beat your Medicare copay — always compare before filling; (4) If your income is below 150% of the federal poverty level, you may qualify for the Medicare Extra Help (Low-Income Subsidy) program, which reduces Part D costs to near-zero.
Ibrance is manufactured by Pfizer. The FDA application number is BLA125057.
Ibrance (Palbociclib) is primarily prescribed for Cancer.
Medicare Part D spending on Ibrance has decreased -5.6% year over year. Total program spending reached $4521.0M in the latest reporting year.
Ibrance (Palbociclib) costs an average of $10,816 per Medicare Part D claim, with total Medicare spending of $4521.0M in the latest year. A generic version is available, which may reduce out-of-pocket costs.
This answer pulls from CMS Medicare Part D Drug Spending data, the authoritative federal source for U.S. Medicare prescription-drug pricing. The headline number above is the direct answer; what follows is the additional context most readers need to use the answer for a real decision rather than just a fact lookup.
For readers turning this answer into action: cross-reference against the underlying CMS Medicare Part D Drug Spending data record before acting on time-sensitive decisions. The site renders the data as it was published; subsequent revisions can shift the picture, and the live federal data is always the authoritative current reference.
Source: CMS Medicare Part D Spending, 2026.